MacrogenicsMGNX -1.93%47 OCF Yield % is -24.08 as of Jul. 09, 2026. GuruFocus rates MGNX with a GF Score™ of 47/100 and a GF Value™ of $4.06 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,408 Biotechnology companies, Macrogenics ranks worse than 71.52% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Macrogenics OCF Yield % Related Terms
Macrogenics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Macrogenics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Macrogenics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Macrogenics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (MGNX) has a OCF Yield % of -24.08 as of Jul. 09, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Macrogenics and its competitors. According to the industry distribution chart, Macrogenics ranks #1007 out of 1408 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Macrogenics' OCF Yield % too high?
Macrogenics' current OCF Yield % is -24.08. Based on the distribution chart, Macrogenics ranks #1007 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' OCF Yield % compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #1007 out of 1408 companies for OCF Yield %. This places Macrogenics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Macrogenics and its competitors. Macrogenics's current OCF Yield % is -24.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (MGNX) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.06, compared to a current price of $4.57 — trading 12.6% above its estimated fair value. The current OCF Yield % is -24.08. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Macrogenics (MGNX), the current OCF Yield % is -24.08 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (MGNX) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of $4.57 is trading 12.6% above its estimated GF Value™ of $4.06.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for MGNX:
OCF Yield %: -24.08
GF Value™: $4.06 vs. price of $4.57 (12.6% above fair value)
No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score
Get the complete analysis for MGNX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGNX has been successfully added to your 
